Hépato-Gastro & Oncologie Digestive
MENUBiopsies and cancer patient decision making Volume 17, issue 5, septembre-octobre 2010
Figures
Unité d'oncologie uro-digestive, CHU Charles Nicolle, 1 rue de Germont, 76000 Rouen
- Key words: digestive oncology, molecular tests, treatment
- DOI : 10.1684/hpg.2010.0478
- Page(s) : 398-403
- Published in: 2010
Complementary molecular analysis to pathology assessment is now recommended in digestive oncology. The aim of these analyses of the tumoral tissue is the detection of prognosis and/or predictive alteration that might be useful in clinical practice. To date, four tests are commonly performed: HER2 expression for trastuzumab in a metastatic gastric cancer, KIT mutations for imatinib in gastrointestinal tumours, microsatellite instability for adjuvant treatment in colorectal cancer, and KRAS mutation for anti-EGFR therapies in metastatic colorectal cancer. For the other malignancies of the gastrointestinal tract, no additional test should be performed in routine basis.